Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

DISSECT-N Post Market Data Collection Registry

NCT04267055 · View on ClinicalTrials.gov ↗

Study Summary

DISSECT-N is a post-market registry designed to assess real-world safety and effectiveness of Valiant Navion Thoracic Stent Graft System in the treatment of thoracic aortic dissections in real world practice.

Conditions Studied

Interventions

  • DEVICE Valiant Navion Thoracic Stent Graft System

Study Locations (20)

Other

  • Rigshospitalet — Copenhagen
  • General Hospital of Athens, Evaggelismos — Athens
  • Ospedale San Raffaele - Milano — Milan
  • Keio University Hospital — Tokyo
  • St. Antonius Ziekenhuis — Nieuwegein
  • Auckland City Hospital — Grafton
  • Narodny Ustav Srdcovych a Cievnych Chorob, A.S. — Bratislava

New York

  • Albany Medical Center — Albany
  • Northwell Health Lenox Hill Hospital — New York

Pennsylvania

  • UPMC Pinnacle Harrisburg Campus — Harrisburg
  • Hospital of the University of Pennsylvania — Philadelphia

Alabama

  • University of Alabama at Birmingham Hospital — Birmingham

Florida

  • University of Florida Health Shands Hospital — Gainesville

Georgia

  • Emory University Hospital — Atlanta

Michigan

  • University of Michigan Health System - University Hospital — Ann Arbor

North Carolina

  • Atrium Health's Carolinas Medical Center — Charlotte

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2020-06-25
Est. Completion 2024-07-05

Sponsor

Medtronic Cardiovascular

49 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04267055

The ClinicalTrials.gov registry entry for NCT04267055 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 49 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Thoracic Aortic Dissection appearing as the primary indexed condition, and to 1 intervention — of which Valiant Navion Thoracic Stent Graft System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04267055 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Other, New York, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04267055 about?

NCT04267055 is a clinical study titled "DISSECT-N Post Market Data Collection Registry". DISSECT-N is a post-market registry designed to assess real-world safety and effectiveness of Valiant Navion Thoracic Stent Graft System in the treatment of thoracic aortic dissections in real world practice.

What is the current status of trial NCT04267055?

This trial is currently completed. The enrollment target is 102 participants. The study started on 2020-06-25. Estimated completion is 2024-07-05.

What conditions does trial NCT04267055 study?

This clinical trial studies the following conditions: Thoracic Aortic Dissection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04267055?

The interventions under investigation include: Valiant Navion Thoracic Stent Graft System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04267055?

This trial is sponsored by Medtronic Cardiovascular, which has 49 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04267055 being conducted?

This trial has 20 study locations across Alabama, Florida, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial